(-)-3'-thiacytidine (use 3TC)
(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (use GS 504)
2-aminopurines - Sep., p. 270
2',3'-didehydro-2',3'-dideoxythymidine (use D4T)
2,5A-antisense oligonucleotide conjugates - July, p. 201
3'-thiacytidine (use 3TC for HIV; lamivudine for hepatitis treatment)
3TC - Apr., p. 97, 98; Nov., p. 321, 322; Dec., p. 362
5-fluorouracil - Oct., p. 289
9-(2-phosphonylmethoxyethyl)adenine (use PMEA)
70K protein, HIV antibodies - Dec., p. 359
256U87 (use valaciclovir)
348U87 - May, p. 135
882C87 - May, p. 135; June, p. 171
A-80987 - Oct., p. 291
ABT-538 - Oct., p. 291
Accell gene guns - Nov., p. 332; Dec., p. 362
AccuSite Injectable Gel - Oct., p. 289
acetylsalicylic acid (use aspirin)
acridine derivatives - Sep., p. 265
acyclovir - May, p. 135; June, p. 171; July, p. 199; Sep., p. 270; Oct., p. 290, 295
acyclovir, controlled release - Aug., p. 231
acyclovir, generic - Feb., p. 41
acyclovir, OTC - Feb., p. 41; July, p. 197
acyclovir, topical - Nov., p. 328
acyclovir/AZT combination - Sep., p. 257; Oct., p. 295
Adatomed Silicone Oil - Dec., p. 363
afovirsen (use ISIS 2105)
AG1343 - Oct., p. 291
AG1350 - Feb., p. 36
ALFERON N Injection - Feb., p. 39
alpha 1-antitrypsin - Oct., p. 297
alum adjuvant - Nov., p. 328
alvercept sudotox [use CD4(178)-PE40]
ALX40-4C - May, p. 138
AM285 - Aug., p. 230
amantadine - Dec., p. 360
Ampligen - Dec., p. 363
antigen-coated diamond particle vaccines - Apr., p. 100
antisense oligonucleotide-2,5A conjugates - July, p. 201
antisense oligonucleotide-asialoglycoprotein conjugates - Aug., p. 232
antisense oligonucleotides - Sep., p. 267
antisense oligonucleotides, CMV - May, p. 130
antisense oligonucleotides, HIV - May, p. 133; July, p. 201; Aug., p. 233; Oct., p. 295
antisense oligonucleotides, viral 5' cap mRNA - Feb., p. 43
aspirin - Aug., p. 231
Astragalus plants - Feb., p. 44
autoimmune immune globulins - Dec., p. 359
autolymphocyte therapy (ALT) - Aug., p. 230
AZT - Mar., p. 65, 67, 71, 73, 74; Apr., p. 97, 99, 103; May, p. 129, 135, 137, 138; July, p. 201, 202; Aug., p. 227; Oct., p. 297, 300; Dec., p. 356
AZT Efficiently Controlled (Aztec) - Dec., p. 358
AZT, generic - Feb., p. 41; Dec., p. 364
AZT-DDI conjugates - Aug., p. 235
AZT/3TC combination - Nov., p. 321
AZT/acyclovir combination - Sep., p. 257; Oct., p. 295
beta2-microglobulin HIV vaccines - Oct., p. 293
BHAP-E (use delaveridine mesylate)
BI-RG-587 (use nevirapine)
BioLogic-HT - Oct., p. 293; Dec., p. 362
bis(POM)PMEA (use GS 840)
bovine immunodeficiency virus vaccine (for HIV) - Nov., p. 329
brominated psoralens - Sep., p. 265
bucast - Mar., p. 68
BV-araU - July, p. 200; Oct., p. 295
calanolides - Apr., p. 106; Sep., p. 270
Calophyllum plants - Sep., p. 270; Dec., p. 360
carrageenan - June, p. 169
castanospermine, 6-O-butanoyl- (use bucast)
CD4 inserted into erythrocytes - Oct., p. 293
CD4 liposomes - Oct., p. 293
CD4(178)-PE40 - Oct., p. 296
CD4+ T-cells, ex vivo expansion - Sep., p. 268
CD4-based therapeutics - Apr., p. 104; Nov., p. 330
cell-transfer immune reconstitution - Feb., p. 38
cholera toxin B vaccine carriers/adjuvants - Mar., p. 77
CMV gB vaccines - Aug., p. 233
CMV IE84 - Sep., p. 267
CMV naked DNA vaccines - Oct., p. 296
CMV protein kinase - July, p. 206
conocurvone - June, p. 170
Conospermun (Smokebush) - June, p. 170
controlled release AZT - Dec., p. 358
costatolides - Apr., p. 106
Croton plants - Dec., p. 360
curcumin - Aug., p. 229
cyclocreatine - Aug., p. 230
cytokines - Aug., p. 228; Nov., p. 331
cytotoxic lymphocyte maturation factor - Feb., p. 36
D4T - Feb., p. 34; June, p. 161; Aug., p. 225
DAB389IL-2 (use IL-2 Fusion Toxin)
DDC - Mar., p. 73; May, p. 137; Aug., p. 226
DDI - Apr., p. 97; May, p. 129, 135, 137; July, p. 202; Dec., p. 356
decoy vaccines - Apr., p. 100
delaveridine mesylate - May, p. 138
deuterium oxide - Apr., p. 102
dideoxyadenosine, 2'-fluoro-2',3'- (use F-ddA)
dideoxyinosine, 2-fluoro-2,3- (use F-ddI)
dideoxynucleosides, dimeric - Aug., p. 235
diphtheria toxin, HIV activated gene - May, p. 139
Disabled Infectious Single Cycle (DISC) vaccines - Sep., p. 268
docosanol - Nov., p. 328
entomopoxvirus vaccine vectors - Mar., p. 71
F-ddA - June, p. 174
F-ddI - June, p. 174
famciclovir - Feb., p. 40; July, p. 193; Sep., p. 270; Nov., p. 325
Famvir (use famciclovir)
fialuridine (use FIAU)
FIAU - June, p. 165, 166
FIV immunodiagnostics - Dec., p. 366
Flumadine - Dec., p. 360
foscarnet, alkyl-glycerol analog - Nov., p. 330
fowlpox virus vaccine vectors - Oct., p. 297
Gamimune N IVIG - Mar., p. 74
ganciclovir - May, p. 138; Sep., p. 264
ganciclovir, implants - Dec., p. 353
ganciclovir, oral - Aug., p. 227; Nov., p. 323
Gastrogard R - Apr., p. 101
GEM 91 - May, p. 133; July, p. 201; Aug., p. 233; Oct., p. 295
gene therapy vectors - May, p. 132; July, p. 200; Oct., p. 301
gene therapy, HIV - Dec., p. 362
Geomatrix (controlled release) - Aug., p. 231
gibbon ape leukemia virus vectors - Oct., p. 301
GLQ223 - May, p. 137
GS 504 - Feb., p. 40; Mar., p. 71; May, p. 138
GS 504, eye drops - Aug., p. 230
GS 804 - Mar., p. 71; Aug., p. 232
guanine, 9-(4-hydroxy-3-hydroxymethylbut-1-yl) (use famciclovir)
Havrix - Feb., p. 35; Dec., p. 362
Hepa-Gen-3 - June, p. 171
hepatitis A vaccines - Feb., p. 35; Mar., p. 73; June, p. 172; Oct., p. 296; Dec., p. 362
hepatitis B reverse transcriptase inhibitors - Mar., p. 74
hepatitis B surface antigen vaccines - June, p. 171, 172; Aug., p. 236; Nov., p. 333
hepatitis B vaccines - Aug., p. 236
hepatitis B vaccines, oral - Feb., p. 41; Mar., p. 73
hepatitis C antibodies - Aug., p. 232
hepatitis C diagnostics - Oct., p. 300; Dec., p. 366
hepatitis C vaccines - Mar., p. 73; Oct., p. 300
hepatitis C vaccines, oral - Feb., p. 41
hepatitis E virus vaccines - Oct., p. 292
herpes simplex virus (use HSV)
HIV alpha-glucosidase I inhibitors - Mar., p. 68
HIV antibodies, 70K protein - Dec., p. 359
HIV bispecific antibodies - Oct., p. 291; Nov., p. 331
HIV furin inhibitors - Oct., p. 297
HIV gene therapy - July, p. 200
HIV gene therapy vaccines - Apr., p. 102; Nov., p. 332
HIV gene therapy, DNA vaccines - Sep., p. 268; Oct., p. 296
HIV gene therapy, retroviral vectors - May, p. 139; Nov., p. 330; Dec., p. 361
HIV gene therapy, T-cells - Sep., p. 268, 270
HIV gp120 radioisotope conjugates - Nov., p. 332
HIV gp120 vaccines - Feb., p. 43
HIV gp160 vaccines - Feb., p. 33; June, p. 164; Aug., p. 231
HIV immune globulins - Feb., p. 37
HIV ImmunoTherapeutic from Viagene [use HIV-IT (V)]
HIV integrase inhibitors - Feb., p. 40
HIV LTR inhibitors - Aug., p. 229
HIV peptomers - Aug., p. 235
HIV porcine immune globulins - Feb., p. 38
HIV protease inhibitors - Feb., p. 34, 36, 40; Mar., p. 69, 70; Apr., p. 97, 102; Aug., p. 235; Sep., p. 261, 262; Oct., p. 291; Nov., p. 326; Dec., p. 360
HIV ribozymes - Sep., p. 267, 268
HIV RNase H inhibitors - Apr., p. 102
HIV Tat inhibitors - May, p. 138
HIV transcription repressors - Sep., p. 265
HIV vaccines - Feb., p. 40; July, p. 204
HIV vaccines, controlled release - Dec., p. 359
HIV vaccines, inactivated - Mar., p. 72; May, p. 138; June, p. 172; Aug., p. 232
HIV vaccines, synthetic peptides - June, p. 171; July, p. 201; Aug., p. 230; Sep., p. 268
HIV vaccines, vaccinia virus vectors - Mar., p. 71; Apr., p. 104
HIV-activated CD8+ T-cells - July, p. 200
HIV-binding phosphorothioate oligonucleotides - Nov., p. 325
HIV-IT (V) - Apr., p. 102; Nov., p. 330; Dec., p. 361
HIVID (use DDC)
HIVMN gp120 vaccine - June, p. 164; July, p. 194; Nov., p. 324; Dec., p. 359
HIVSF gp120 vaccine - June, p. 164; July, p. 194; Nov., p. 324, 328
Homalnthus plants - Aug., p. 235
HPMPC (use GS 504)
HSV UL13 protein kinase - July, p. 206
HSV vaccines - Sep., p. 264
HSV VP16 transactivator protein - Apr., p. 101
HSV-2 DISC vaccine - Sep., p. 268
HSV-2 gD vaccine - June, p. 168; Nov., p. 327
hypericin, oral - Apr., p. 103
hyperthermia, whole-body extracorporeal - Oct., p. 293; Dec., p. 362
IL-2 Fusion Toxin - Feb., p. 41
IL-2 gene therapy - Sep., p. 270
IL-2, polyethylene glycol-modified - Mar., p. 73
immune globulin and peripheral blood lymphocytes - Feb., p. 38
immune globulins, autoimmune - Dec., p. 359
immune globulins, RSV - July, p. 200
immune modulators - Feb., p. 36; July, p. 201
immunomodulatory polysaccharides - Feb., p. 44
Immupath - Feb., p. 37
influenza vaccines - June, p. 170; Aug., p. 233; Sep., p. 264
interferon, alfa-n1 - June, p. 169
interferon, alfa-n3 - Feb., p. 39; May, p. 140
interferon, alpha - Mar., p. 73
interferon, alpha-2a - June, p. 169
interferon, alpha-2b - Mar., p. 73; May, p. 131; June, p. 169; Dec., p. 357
interferon, leukocyte-derived - May, p. 140
interferon, lymphoblastoid - June, p. 169; Dec., p. 357
interleukin-10 - Aug., p. 235
interleukin-12 - Feb., p. 36
interleukin-2 (use IL-2)
Intron A (use interferon, alpha-2b)
ISIS 2105 - Aug., p. 233
ISIS 2922 - May, p. 130
ISIS 5320 - Nov., p. 325
Kaposi's sarcoma-associated virus - Dec., p. 355
KNI-272 - Dec., p. 360
kynostatin - Dec., p. 360
L-735,524 - Feb., p. 40; Mar., p. 69; Apr., p. 97
lamivudine - Nov., p. 324
LeukoVir-MB Filter - Sep., p. 266
LIDAKOL - Nov., p. 328
Liposome-CD4 - Oct., p. 293
liposome-encapsulated MPL adjuvant - Nov., p. 328
MDX-240 - Oct., p. 291; Nov., p. 331
measles/mumps/rubella vaccines - June, p. 172; Dec., p. 362
metal poly-oxometallates - Oct., p. 296
methylene blue - Sep., p. 266
MF59 adjuvant - July, p. 194; Aug., p. 233; Nov., p. 328
monoclonal antibodies, human-like - July, p. 204
monophosphoryl lipid A - Nov., p. 327, 328
muramyl tripeptide phosphatidylethanolamine - Nov., p. 328
n-docosanol - Nov., p. 328
naked DNA vaccines - May, p. 141
natural killer-cell stimulatory factor - Feb., p. 36
nevirapine - Apr., p. 97; May, p. 135; Dec., p. 356
nojirimycin, N-butyldeoxy- - Mar., p. 68
OPC-8212 (use vesnarinone)
Oral Vironostika HIV-1 Microelisa System - Dec., p. 363
OraSure HIV Oral Specimen Collection Device - Dec., p. 363
oxoferin - Dec., p. 359
PASSHIV-1 - Feb., p. 38
penciclovir - July, p. 193
peptoid compounds - Nov., p. 330
phorbol-13-acetate, 12-deoxy- (use prostratin)
phosphorothioate oligonucleotides, HIV-binding - Nov., p. 325
photoinactivation, blood - Apr., p. 103; Sep., p. 265
PIC 024 - Apr., p. 104; Nov., p. 330
PKR, interferon-inducer - Sep., p. 269
platinum complexes - Oct., p. 296
PMEA - Mar., p. 71
PMEA, bis pivaloyoxylmethyl (use GS 804)
poliovirus vaccine, inactivated (IPV) - Apr., p. 102
poly ADP-ribosyl transferase - Dec., p. 363
poly I:poly (C12U) - Dec., p. 363
poly(lactic-coglycolic)acid microsphere vaccines - Dec., p. 359
polyethylene glycol-modified IL-2 - Mar., p. 73
polymer-based drug, oral - Nov., p. 332
proanthocyanidin polymers - Dec., p. 360
ProScan-A - Nov., p. 332
prostratin - Aug., p. 235
ProSys - Apr., p. 104
protein kinase, interferon-induced - Sep., p. 269
Provax HIV gp120 vaccine - Feb., p. 43
Provir - Dec., p. 360
PRV/Marker - Apr., p. 103
pseudorabies vaccines - Apr., p. 103
psoralens, protein activated - Sep., p. 266
pyridinone (use L-735,524)
pyrimidinedione, 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodo-2,4(1H,3H)- (use FIAU)
pyrimidones, dibenzyl-5-hydroxyl-2- - Aug., p. 235
QS-21 Stimulon adjuvant - July, p. 202; Dec., p. 359
Quantiplex HSV RNA - Oct., p. 300
quinolinone, 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)- (use vesnarinone)
rabies vaccines - Feb., p. 39; June, p. 172
Rabipur - Feb., p. 39
RBC-CD4 - Oct., p. 293
Recombivax-HB - June, p. 172
red algae (Rhodophyta) - June, p. 169
red blood cells-CD4 - Oct., p. 293
RespiGam - July, p. 200; Sep., p. 264; Oct., p. 296
reverse transcriptase inhibitors, non-nucleosides - Mar., p. 74; Apr., p. 103; May, p. 138
rhinovirus type 14 3C protease - Mar., p. 70
ribavirin, aerosol - Aug., p. 233
ribavirin, oral - June, p. 171
rimantadine HCl - Dec., p. 360
Ro 31-8959 (use saquinavir)
Roferon A (use interferon, alpha-2a)
rotavirus bovine colustrum - Apr., p. 101
rotavirus vaccines - Nov., p. 331
RP400c - Aug., p. 230
RSV Fab single-chain antibody fragments - Mar., p. 72
RSV immune globulins - July, p. 200; Sep., p. 264; Oct., p. 296
RSV single-chain antibody fragments - July, p. 205
SAF/2 adjuvant - Nov., p. 328
saquinavir - Apr., p. 97; Sep., p. 259, 261; Nov., p. 326; Dec., p. 356
SC-52151 - Nov., p. 326
Scriptene - Aug., p. 235
selenocysteine - Sep., p. 265
serum thiols assay - Dec., p. 363
SIV vaccines, vaccinia virus vectors - Mar., p. 71
sorivudine (use BV-araU)
SP-303 - Dec., p. 360
stavudine (use D4T)
Stimulon adjuvants - July, p. 202; Dec., p. 359
sulfated polysaccharides - June, p. 169
Sumiferon - June, p. 169
swinepox vaccine vectors - Mar., p. 71
Symmetrel - Dec., p. 360
synovir (use thalidomide)
TBC-3B - Mar., p. 71
tetrachlorodecaoxygen - Dec., p. 359
thalidomide - Apr., p. 102; Oct., p. 297
threonyl muramyl dipeptide adjuvant - Nov., p. 328
thymosin alpha 1 - Mar., p. 73; May, p. 131; Sep., p. 264; Dec., p. 357
tragacanth gums - Feb., p. 44
transcription inhibitors - Apr., p. 101
TRAx CD4 and CD8 diagnostics - Mar., p. 74
trichosanthin (use GLQ223)
tumor suppressor protein p53 - Sep., p. 267
U-90,152 (use delaveridine mesylate)
uracil, (E)-5-(2-bromovinyl)arabinofuranosyl (use BV-araU)
Usevir (use BV-araU) - July, p. 200
vaccines, retroviral vectors - May, p. 132
vaginal gels, antiviral - June, p. 169
valaciclovir - May, p. 135; July, p. 202
Valtrex (use valaciclovir)
Vaqta - Mar., p. 73
varicella-zoster virus (use VZV)
Varivax - Feb., p. 35
VaxSyn HIV-1 - Feb., p. 33; June, p. 164
VectorVax FP-N - Oct., p. 297
vesnarinone - May, p. 134
Videx (use DDI)
ViraCHEK/FIV immunodiagnostics - Dec., p. 366
viral inactivation, blood - Sep., p. 266
Virazole (use ribavirin)
Virend - Dec., p. 360
VZV protein kinase - July, p. 206
VZV vaccines - Feb., p. 35
Zerit (use D4T)
Zonavir (use 882C87)